Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H2, 2018

GlobalData's clinical trial report, “Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H2, 2018" provides an overview of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Jiangsu Hengrui Medicine Co Ltd

Pfizer Inc

Laboratoires Dermatologiques d'Uriage

Johnson & Johnson

Hanmi Science Co Ltd

F. Hoffmann-La Roche Ltd

Cromsource Srl

Bayer AG ...

Jiangsu Hengrui Medicine Co Ltd

Pfizer Inc

Laboratoires Dermatologiques d'Uriage

Johnson & Johnson

Hanmi Science Co Ltd

F. Hoffmann-La Roche Ltd

Cromsource Srl

Bayer AG

Ajinomoto Co Inc

Advancell

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region ...

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials 21

Clinical Trials by Phase in E7 Countries 23

Clinical Trials in E7 Countries by Trial Status 24

Clinical Trials by Phase 25

In Progress Trials by Phase 26

Clinical Trials by Trial Status 27

Clinical Trials by End Point Status 29

Subjects Recruited Over a Period of Time 30

Clinical Trials by Sponsor Type 31

Prominent Sponsors 32

Top Companies Participating in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials 34

Prominent Drugs 36

Clinical Trial Profile Snapshots 38

Appendix 66

Abbreviations 66

Definitions 66

Research Methodology 67

Secondary Research 67

About GlobalData 68

Contact Us 68

Source 69

List of Tables

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2018* 8

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and ...

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2018* 8

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 12

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2018* 14

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 15

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 16

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, G7 Countries (%), 2018* 17

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, E7 Countries (%), 2018* 22

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2018* 26

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

List of Figures

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials ...

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 12

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, G7 Countries (%), 2018* 17

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, E7 Countries (%), 2018* 22

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

GlobalData Methodology 68

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports